CAN­bridge ex­pands rare dis­ease pact with WuXi Bi­o­log­ics; Watch for a man­u­fac­tur­ing site from Al­lo­gene

→ Just four months af­ter ink­ing its rare dis­ease-fo­cused co-de­vel­op­ment part­ner­ship with WuXi Bi­o­log­ics, CAN­bridge Phar­ma is adding four projects to the mix. Promis­ing the whole pack­age of up­front, mile­stones and roy­al­ties, CAN­bridge will get ex­clu­sive re­gion­al or glob­al rights for rare ge­net­ic chron­ic dis­ease ther­a­pies de­vel­oped by WuXi, which will sup­ply the drugs for this year.

→ What’s to come of the over $700 mil­lion Arie Bellde­grun and David Chang have raised for Al­lo­gene Ther­a­peu­tics $AL­LO? Why, a man­u­fac­tur­ing site for their off-the-shelf CAR-T cell ther­a­pies, of course. And it will be built in the Bay Area, CEO Chang told at­ten­dees of his pre­sen­ta­tion at JP Mor­gan, with de­tails to come in the “near fu­ture.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER